← Back to Search

Other

PF-06873600 + Hormone Therapy for Breast Cancer

Phase 2
Waitlist Available
Research Sponsored by Pfizer
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
• Prior combined CDK 4/6 inhibitor and endocrine therapy and 1 or 2 prior lines of chemotherapy
Have a diagnosis of advanced platinum resistant epithelial ovarian cancer (EOC)/fallopian tube cancer/primary peritoneal cancer (PPC)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline up to approximately 24 months
Awards & highlights

Study Summary

This trial is testing a new medicine to see if it's safe and effective when taken alone or with hormone therapy by people with different types of cancer.

Who is the study for?
This trial is for people with certain advanced cancers, including HR+ HER2- breast cancer, triple negative breast cancer, and ovarian/fallopian tube/peritoneal cancers. Participants should have had prior treatments like CDK 4/6 inhibitors or chemotherapy but not be currently undergoing other trials or recent surgeries.Check my eligibility
What is being tested?
The study tests PF-06873600 alone or with hormone therapies (letrozole taken daily by mouth or fulvestrant given as a monthly shot) in patients with specific types of advanced cancer. The treatment period lasts at least 7 to 8 months with weekly clinic visits.See study design
What are the potential side effects?
Possible side effects are not detailed here but may include typical reactions to oral medications and hormone therapy such as gastrointestinal issues, fatigue, hormonal imbalances, injection site reactions, and potential drug-specific adverse effects.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I've had CDK 4/6 inhibitor and hormone therapy, plus 1 or 2 chemotherapy treatments.
Select...
I have advanced ovarian, fallopian tube, or peritoneal cancer that is resistant to platinum-based chemotherapy.
Select...
My cancer can be measured or is not responding to current treatments.
Select...
I have metastatic triple negative breast cancer and received up to 2 chemotherapy treatments.
Select...
I have been diagnosed with metastatic triple negative breast cancer.
Select...
My breast cancer is hormone receptor positive and HER2 negative.
Select...
My breast cancer is HR+ and HER2- and I've had specific prior treatments.
Select...
I have advanced ovarian, fallopian tube, or peritoneal cancer resistant to platinum therapy, with 2-3 prior treatments.
Select...
I have had 1 or 2 chemotherapy treatments before.
Select...
I am fully active or restricted in physically strenuous activity but can do light work.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline up to approximately 24 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline up to approximately 24 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of patients with dose limiting toxicities in the Dose Escalation portion
Objective Response Rate (ORR) observed in patients in the Dose Expansion Arms
Safety and Tolerability as assessed by adverse event monitoring for patients enrolled in the Dose Escalation, Dose Finding and Dose Expansion Arms
+5 more
Secondary outcome measures
Upper arm
Multiple Dose: Accumulation Ratio (Rac (AUCss,t /AUCsd,t)) in the Dose Escalation and Dose Finding portion and Dose Expansion Arms
Multiple Dose: Apparent Volume of Distribution at Steady State (Vss/F) in the Dose Escalation and Dose Finding portion and Dose Expansion Arms
+19 more

Trial Design

8Treatment groups
Experimental Treatment
Group I: Dose Finding Endocrine Therapy 2 CombinationExperimental Treatment2 Interventions
Part 1B PF-06873600 plus Endocrine Therapy 2
Group II: Dose Finding Endocrine Therapy 1 CombinationExperimental Treatment2 Interventions
Part 1B PF-06873600 plus Endocrine Therapy 1
Group III: Dose Expansion Arm EExperimental Treatment2 Interventions
PF-06873600 in Combination with Endocrine Therapy 2
Group IV: Dose Expansion Arm DExperimental Treatment2 Interventions
PF-06873600 in Combination with Endocrine Therapy 1
Group V: Dose Expansion Arm CExperimental Treatment2 Interventions
PF-06873600 in Combination with Endocrine Therapy 1
Group VI: Dose Expansion Arm BExperimental Treatment1 Intervention
PF-06873600 as a Single Agent in Various Tumor Types
Group VII: Dose Expansion Arm AExperimental Treatment1 Intervention
PF-06873600 as a Single Agent
Group VIII: Dose EscalationExperimental Treatment1 Intervention
Single Agent Dose Escalation

Find a Location

Who is running the clinical trial?

PfizerLead Sponsor
4,567 Previous Clinical Trials
10,911,719 Total Patients Enrolled
111 Trials studying Breast Cancer
36,404 Patients Enrolled for Breast Cancer
Pfizer CT.gov Call CenterStudy DirectorPfizer
3,474 Previous Clinical Trials
8,092,887 Total Patients Enrolled
43 Trials studying Breast Cancer
12,808 Patients Enrolled for Breast Cancer

Media Library

PF-06873600 (Other) Clinical Trial Eligibility Overview. Trial Name: NCT03519178 — Phase 2
Breast Cancer Research Study Groups: Dose Expansion Arm C, Dose Expansion Arm D, Dose Expansion Arm A, Dose Expansion Arm B, Dose Finding Endocrine Therapy 1 Combination, Dose Escalation, Dose Expansion Arm E, Dose Finding Endocrine Therapy 2 Combination
Breast Cancer Clinical Trial 2023: PF-06873600 Highlights & Side Effects. Trial Name: NCT03519178 — Phase 2
PF-06873600 (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03519178 — Phase 2
Breast Cancer Patient Testimony for trial: Trial Name: NCT03519178 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What potential risks are associated with the use of PF-06873600?

"PF-06873600 has been determined to be a safety level 2 on the scale of 1 to 3. This is due to its Phase 2 status, as there's evidence that suggests it is safe, but none confirming efficacy."

Answered by AI

How many healthcare facilities are involved in this investigation?

"This study is actively recruiting from numerous sites, such as Northwest Medical Specialties, PLLC in Federal Way; Virginia G. Piper Cancer Center Pharmacy in Scottsdale; Rainier Hematology-Oncology PC in Puyallup and an additional thirty nine other locations."

Answered by AI

Are there any vacancies within this research program for participants?

"The details published on clinicaltrials.gov indicate that this research is no longer accepting participants, with the original post date being on March 7th 2018 and most recent update having occured in November 21st 2022. Fortunately, there are 2838 other studies actively recruiting at present."

Answered by AI

Who else is applying?

What state do they live in?
Arizona
What site did they apply to?
UCLA Hematology/Oncology - Parkside
What portion of applicants met pre-screening criteria?
Did not meet criteria
How many prior treatments have patients received?
2

Why did patients apply to this trial?

Looking for treatment options for prevention and to help progress in treatment in general for others with this disease.
PatientReceived no prior treatments
Recent research and studies
clinicaltrials.govStudy
A Study of PF-06873600 in People With Cancer
2018. "A Study of PF-06873600 in People With Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03519178.
All > Fallopian Tube Cancer > Paid Studies Arkansas
~22 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top